Clinical, Angiographic, and Procedural Correlates of Very Late Absorb Scaffold Thrombosis: Multistudy Registry Results.
Explore this paper's citation graph
Summary
In the present analysis, the largest to date of its type, relative scaffold undersizing was the strongest determinant of VLST, and likely has ramifications for all bioresorbable scaffolds.
- Type
- article
- Published
- 2018-04-09
- Cited by
- 22
- References
- 20
- Access
- Open access
- OpenAlex
- https://openalex.org/W29622141
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4614358
Keywords
Computer science
References
- Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent
- Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis.
- OCT analysis in patients with very late stent thrombosis.
- Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement
- Regression modelling strategies for improved prognostic prediction.
- Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
- Edge detection versus densitometry in the quantitative assessment of stenosis phantoms: an in vivo comparison in porcine coronary arteries.
- Very Late Thrombosis After Bioresorbable Scaffolds: Cause for Concern?
- Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings.
- Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
- Relation Between Bioresorbable Scaffold Sizing Using QCA-Dmax and Clinical Outcomes at 1 Year in 1,232 Patients From 3 Study Cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II).
- 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.
- Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors.
- Intraluminal Scaffold Dismantling: The Downside of Positive Remodeling?
- Very Late Bioresorbable Scaffold Thrombosis Caused by Intraluminal Scaffold Dismantling.
- Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial.
- 10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents.
- Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score.
- Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis.
- Characteristics, Predictors, and Mechanisms of Thrombosis in Coronary Bioresorbable Scaffolds: Differences Between Early and Late Events.
Cited by
- Bioresorbable Vascular Scaffolds: Back to the Drawing Board.
- Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
- The future of vascular restoration therapy.
- Predictors of stent thrombosis and their implications for clinical practice
- Three to four years outcomes of the absorb bioresorbable vascular scaffold versus second‐generation drug‐eluting stent: A meta‐analysis
- Incidental Finding of Strut Malapposition Is a Predictor of Late and Very Late Thrombosis in Coronary Bioresorbable Scaffolds
- Hybrid Coronary Percutaneous Treatment with Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-Years Results from the GABI-R Registry
- Magnesium-Based Resorbable Scaffold versus Permanent Metallic SirolimusEluting Stent in Patients with ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial.
- Bioresorbable Vascular Scaffolds—Dead End or Still a Rough Diamond?
- Five Years Outcomes and Predictors of Events in a Single-Center Cohort of Patients Treated with Bioresorbable Coronary Vascular Scaffolds
- Bioresorbable Scaffolds: Current Technology and Future Perspectives
- Three-year outcomes of bioresorbable vascular scaffolds versus second-generation drug-eluting stents
- A systematic review and meta-analysis of bioresorbable vascular scaffolds for below-theknee arterial disease.
- Thin-Strut BRS: Revival of a Failed Revolution?
- Polymer–Metal Composite Healthcare Materials: From Nano to Device Scale
- Bioresorbable scaffolds: current concepts and future technology
- Thrombosis and myocardial infarction: the role of bioresorbable scaffolds
- Safety and Efficacy of Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Second-Generation Drug-Eluting Stents in Real-World Practice
- Challenges and chances coexist: A visualized analysis and bibliometric study of research on bioresorbable vascular scaffolds from 2000 to 2022
- Long-Term Results of Bioresorbable Vascular Scaffolds in Patients With In-Stent Restenosis: The RIBS VI Study.
Related papers
No related papers recorded.